Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by standudu
Group name EquipeAT
Item Type Journal Article
Title [Portal vein embolization: Present and future]
Creator Piron et al.
Author Lauranne Piron
Author Emmanuel Deshayes
Author Laure Escal
Author Regis Souche
Author Astrid Herrero
Author Marie-Ange Pierredon-Foulongne
Author Eric Assenat
Author Ngo le Lam
Author Boris Guiu
Abstract Portal vein embolization consists of occluding a part of the portal venous system in order to achieve the hypertrophy of the non-embolized liver segments. This technique is used during the preoperative period of major liver resection when the future remnant liver (FRL) volume is insufficient, exposing to postoperative liver failure, main cause of death after major hepatectomy. Portal vein embolization indication depends on the FRL, commonly assessed by its volume. Nowadays, FRL function evaluation seems more relevant and can be measured by 99mTc labelled mebrofenin scintigraphy. Portal vein embolization procedure is mostly performed with percutaneous trans-hepatic access by using ultrasonography guidance and consists of embolic agent injection, such as cyanoacrylate, in the targeted portal vein branches with fluoroscopic guidance. It is a safe and well-tolerated technique, with extremely low morbi-mortality. Portal vein embolization leads to sufficient FRL hypertrophy in about 80% of patients, allowing them to undergo surgery from which they were initially rejected. The two main reasons of non-resection are tumor progression (?15% of cases) and FRL insufficient hypertrophy (?5% of cases). When portal vein embolization is not enough to obtain adequate FRL regeneration, hepatic vein embolization may potentiate its effect (liver venous deprivation technique).
Publication Bulletin Du Cancer
Volume 104
Issue 5
Pages 407-416
Date May 2017
Journal Abbr Bull Cancer
Language fre
DOI 10.1016/j.bulcan.2017.03.009
ISSN 1769-6917
Short Title [Portal vein embolization
Library Catalog PubMed
Extra PMID: 28477870
Tags Chemotherapy, Adjuvant, clinic, Cyanoacrylates, Embolisation portale, Embolization, Therapeutic, Futur foie restant, Future remnant liver, Hepatectomy, Hepatocarcinoma, Hépatocarcinome, Humans, Hypertrophy, Imino Acids, Liver, Liver Failure, Liver metastases, Liver Neoplasms, Liver Regeneration, Liver resection, Métastases hépatiques, Middle Aged, Organotechnetium Compounds, Portal Vein, Portal vein embolization, Preoperative Care, Résection hépatique
Date Added 2019/05/29 - 14:22:39
Date Modified 2019/05/29 - 15:18:57
Notes and Attachments PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés